Laventatug (BRY-812 Antibody) is a humanized IgG1-kappa monoclonal antibody targeting hSLC39A6. Laventatug serves as the antibody component for the synthesis of the ADC molecule BRY-812 and exhibits anti-tumor activity [1].
In Vitro, BRY812 is an ADC targeting SLC39A6 that significantly inhibits the growth, stemness, and metastasis of colorectal cancer cells[2].
References:
[1]. World Health Organization. WHO Drug Information: Volume 38[M]. World Health Organization, 2024.
[2]. Liu X, et al. Investigation of the cytotoxic effects and mechanisms of the SLC39A6-targeting ADC drug BRY812 in CRC. Sci Rep. 2025 May 25;15(1):18275.
In Vitro, BRY812 is an ADC targeting SLC39A6 that significantly inhibits the growth, stemness, and metastasis of colorectal cancer cells[2].
References:
[1]. World Health Organization. WHO Drug Information: Volume 38[M]. World Health Organization, 2024.
[2]. Liu X, et al. Investigation of the cytotoxic effects and mechanisms of the SLC39A6-targeting ADC drug BRY812 in CRC. Sci Rep. 2025 May 25;15(1):18275.